YOLFTbeta
Sprint Bioscience AB

Sprint Bioscience AB

SPRINT · ST · Healthcare / Biotechnology

3.87SEK+0.09 (+2.38%)

Price History

Full chart

Market Stats

Previous Close3.78
Open3.84
Day Range3.75 – 3.95
52-Week Range0.572 – 4.59
Volume566.28K
Market Cap365.08M
P/E (TTM)4.94
Forward P/E0.00
EPS0.70
Dividend Yield0.00%
Beta-0.57
50-Day Avg3.23
200-Day Avg2.91

About

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases. It is also developing STK25, which is in preclinical trial to treat metabolic liver disease that can lead to inflammation and fibrosis; and TREX1, which is in preclinical trial for the treatment of solid tumors and immuno-oncology. The company has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is headquartered in Huddinge, Sweden.

Company Details

Leadership

  • Mr. Johan EmilssonChief Executive Officer · b. 1984
  • Prof. Pär NordlundFounder · b. 1958
  • Dr. Martin AnderssonCo-Founder, Research Director & Chief Scientific Officer · b. 1971
  • Dr. Kenth HallbergFounder & Director of Structural Chemistry · b. 1971
  • Ms. Jenni BjornulfsonChief Financial Officer · b. 1971
  • Ms. Anne-Marie WenthzelChief Business Officer · b. 1964

Financials

Income Statement

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.37M1.59M2.37M4.61M7.73M34.99M23.97M17.94M33.54M16.89M35.11M83.00K50.48M65.64M167.17M
Growth (%)--32.92%+49.28%+94.43%+67.61%+352.88%-31.51%-25.16%+87.00%-49.66%+107.96%-99.76%+60725.30%+30.02%+154.67%
Cost of Revenue394.78K-2.16M-3.42M-1.17M-207.54K418.46K2.99M745.00K8.17M10.46M10.44M60.99M8.70M28.34M69.84M
Gross Profit1.97M3.75M5.79M5.78M7.93M34.57M20.98M17.19M25.37M6.43M24.68M-60.91M41.79M37.30M97.33M
Gross Margin83.33%236.23%244.29%125.28%102.69%98.80%87.53%95.85%75.63%38.06%70.28%-73384.34%82.77%56.83%58.22%
Operating Expense3.51M8.99M9.95M17.03M23.29M30.01M31.65M39.25M45.79M44.10M50.14M042.63M56.97M0
Operating Income-1.54M-5.24M-4.16M-11.26M-15.36M4.57M-10.67M-22.06M-20.42M-37.67M-25.47M-60.91M-845.00K-19.67M97.33M
Operating Margin-65.10%-329.68%-175.28%-244.24%-198.75%13.05%-44.51%-122.99%-60.88%-223.13%-72.52%-73384.34%-1.67%-29.96%58.22%
EBITDA-1.53M-5.17M-3.85M-10.87M-15.15M5.08M-10.06M-31.06M-19.59M-38.05M-24.49M-60.00M396.00K-17.32M98.40M
EBITDA Margin-64.65%-325.23%-162.26%-235.76%-196.04%14.51%-41.96%-173.19%-58.39%-225.37%-69.75%-72286.75%0.78%-26.38%58.86%
Net Income-1.38M-3.55M-4.39M-11.46M-15.50M4.54M-10.66M-22.22M-22.74M-46.23M-25.35M-60.17M-438.00K-18.28M91.74M
Net Income Margin-58.15%-223.21%-185.03%-248.67%-200.61%12.98%-44.49%-123.86%-67.81%-273.81%-72.20%-72493.98%-0.87%-27.84%54.88%
R&D---400.40K-2.88M---------
R&D as % of Total Revenue---8.69%-8.24%---------
Interest Expense3.46K24.55K231.00K208.81K144.55K84.69K42.00K137.00K1.21M3.44M269.00K42.00K387.00K40.00K6.21M
Interest Expense % of Total Revenue0.15%1.55%9.74%4.53%1.87%0.24%0.18%0.76%3.60%20.38%0.77%50.60%0.77%0.06%3.71%

Balance Sheet

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.77M4.30M7.47M25.15M30.63M49.52M35.48M59.29M19.24M33.40M79.14M37.42M62.38M42.05M136.66M
Total Liabilities746.09K3.20M4.11M4.83M25.81M21.03M7.40M22.05M8.23M24.25M8.68M9.23M34.60M32.78M17.48M
Total Equity2.03M1.10M3.36M20.32M4.82M28.49M28.09M37.24M11.02M9.14M70.45M28.19M27.77M9.27M119.18M
Cash71.81K2.49K603.00K13.98M7.63M23.61M1.48M14.69M8.38M27.07M70.64M29.49M49.93M25.06M126.70M
Total Debt142.39K502.26K2.50M2.31M1.54M769.23K-12.00M-10.00M-----
Net Debt70.57K499.77K1.90M-11.67M-6.09M-22.84M-1.48M-2.69M-8.38M-17.07M-70.64M-29.49M-49.93M-25.06M-126.70M

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.29M-3.57M-10.76M833.54K7.93M-23.05M-19.08M-28.00M-32.22M-40.12M-59.05M22.87M-23.36M83.53M
Investing Cash Flow-392.00K-4.29M-4.05M-6.19M-9.91M-8.56M-11.08M-389.00K-2.71M-2.71M0-2.45M-1.30M-54.00K
Financing Cash Flow2.61M8.46M28.23M-769.23K17.78M9.49M43.37M22.08M50.92M86.39M17.90M24.00K-225.00K18.17M
Capital Expenditure2.64M4.29M4.05M6.19M9.91M8.56M11.08M93.00K2.71M2.71M2.00K2.45M1.30M94.00K
Free Cash Flow-4.93M-7.85M-14.81M-5.36M-1.97M-31.62M-30.16M-28.10M-32.22M-42.82M-59.05M20.42M-24.65M83.44M
FCF to OCF215.10%220.25%137.64%-642.52%-24.88%137.15%158.04%100.33%100.00%106.75%100.00%89.27%105.55%99.89%

Earnings

Report DateMay 20, 2015Aug 26, 2015Nov 18, 2015Feb 24, 2016May 18, 2016Aug 24, 2016Nov 16, 2016Feb 22, 2017May 17, 2017Aug 23, 2017Nov 15, 2017Feb 7, 2018May 16, 2018Aug 15, 2018Oct 24, 2018Feb 20, 2019May 15, 2019Aug 21, 2019Oct 23, 2019Feb 19, 2020May 13, 2020Aug 26, 2020Oct 28, 2020Feb 17, 2021May 12, 2021Aug 13, 2021Oct 27, 2021Feb 16, 2022May 11, 2022Aug 24, 2022Oct 26, 2022Feb 15, 2023May 10, 2023Aug 24, 2023Oct 25, 2023Feb 14, 2024May 8, 2024Aug 28, 2024Oct 30, 2024Feb 12, 2025May 27, 2025Aug 27, 2025Nov 25, 2025Feb 11, 2026May 25, 2026Jun 30, 2026
EPS Estimate------------------------0.29---0.34-0.34-0.34-0.29-0.29---------------
EPS Actual-0.44-0.57-0.30-0.46-0.320.450.060.290.110.10-0.58-0.710.70-0.71-0.66-0.80-0.610.35-0.49-0.73-0.69-0.96-0.34-0.55-0.61-0.57-0.65-0.65-0.65-0.55-0.55-0.30-0.18-0.170.41-0.07-0.04-0.08-0.07-0.06-0.08-0.08-0.081.07-0.12-0.15
Surprise------------------------89.66%---91.18%-91.18%-91.18%-89.66%-89.66%---------------
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap365.08M
Enterprise Value207.46M
Trailing P/E4.94
Forward P/E0.00
Price / Sales2.62
Price / Book3.34
EPS0.70
Book Value0.834
Revenue (TTM)139.36M
Gross Profit (TTM)131.98M
EBITDA79.99M
Profit Margin54.29%
Operating Margin-331720.00%
Return on Equity144.95%
Return on Assets69.03%
Shares Outstanding105.52M
Shares Float93.41M
Beta-0.57
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 3, 2025784:771
  • Oct 27, 2022356:303
  • Aug 12, 202121:20
  • May 28, 2020816:751